MLYS
Mineralys Therapeutics, Inc. Common StockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$2.08B
P/E Ratio
—
EPS
$-1.97
Beta
0.56
52W High
$47.65
52W Low
$12.59
50-Day MA
$27.87
200-Day MA
$32.98
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Mineralys Therapeutics, Inc. Common Stock
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. The company is headquartered in Radnor, Pennsylvania.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-171.45M |
| Operating Margin | 0.00% |
| Return on Equity | -31.00% |
| Return on Assets | -21.30% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $7.93 |
| Price-to-Book | 3.26 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -7.41 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $88.16M |
| Float | $60.37M |
| % Insiders | 0.67% |
| % Institutions | 109.61% |
Historical Volatility
HV 10-Day
89.94%
HV 20-Day
82.98%
HV 30-Day
78.48%
HV 60-Day
73.36%
HV Rank
—
Volatility is currently expanding
Analyst Ratings
Consensus ($49.00 target)
9
Buy1
HoldMore HEALTHCARE Stocks
Data last updated: 6/13/2026